FY2025 EPS Estimates for TSE:TH Raised by Leede Financial

Theratechnologies Inc. (TSE:TH) – Leede Financial upped their FY2025 earnings estimates for Theratechnologies in a report released on Wednesday, December 4th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $0.10 for the year, up from their prior estimate of $0.09. The consensus estimate for Theratechnologies’ current full-year earnings is $0.03 per share. Leede Financial also issued estimates for Theratechnologies’ FY2026 earnings at $0.31 EPS.

Theratechnologies (TSE:TH) last issued its earnings results on Thursday, October 10th. The company reported C$0.09 earnings per share (EPS) for the quarter. Theratechnologies had a negative return on equity of 1,116.86% and a negative net margin of 8.47%. The company had revenue of C$30.96 million during the quarter.

Theratechnologies Trading Up 3.5 %

Shares of TSE:TH opened at C$2.07 on Thursday. The company has a quick ratio of 0.64, a current ratio of 1.10 and a debt-to-equity ratio of 562.07. Theratechnologies has a 52-week low of C$1.59 and a 52-week high of C$3.43. The stock has a market cap of C$95.18 million, a price-to-earnings ratio of -11.11, a PEG ratio of -8.50 and a beta of 1.73. The business has a 50-day moving average price of C$1.73 and a 200-day moving average price of C$1.79.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.